Sign in

CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
operating
EIN
823562771
Phone
(650) 457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. SCHEDULE 13G Stake Statement of Beneficial Ownership
  2. 10-Q Report Quarterly Report
  3. 8-K Event Results of operations
  4. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  5. 4 Open-market sale CHIEF FINANCIAL OFFICER sold 36,342 shares at $1.34 ($48,698)
  6. 144 Insider Sale of Securities
  7. SCHEDULE 13D/A Stake Beneficial Ownership Report
  8. 8-K Event Executive or director change
  9. 4 Open-market sale SVP, General Counsel sold 29,697 shares at $2.12 ($62,958)
  10. 144 Insider Sale of Securities
  11. EFFECT Other Notice of Effectiveness
  12. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  13. S-3 Offering Registration Statement
  14. 10-Q Report Quarterly Report
  15. 8-K Event Results of operations
  16. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  17. SCHEDULE 13G Stake Statement of Beneficial Ownership
  18. 4 Derivatives Options or other derivatives
  19. 4 Option exercise Director acquired 47,700 shares (option exercise)
  20. 4 Derivatives Options or other derivatives

Page 1 of 30 · 587 filings